This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louie, A.
Right arrow Articles by Miller, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louie, A.
Right arrow Articles by Miller, M. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1999, p. 2841-2847, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Interaction between Fluconazole and Amphotericin B in Mice with Systemic Infection Due to Fluconazole-Susceptible or -Resistant Strains of Candida albicans

Arnold Louie,1,2,* Partha Banerjee,1,2 George L. Drusano,1,3 Mehdi Shayegani,2 and Michael H. Miller1,3

Division of Infectious Diseases1 and Clinical Pharmacology,3 Department of Medicine, Albany Medical College, Albany, New York 12208, and Wadsworth Center, New York State Department of Health, Albany, New York 122012

Received 10 July 1998/Returned for modification 13 December 1998/Accepted 8 September 1999

The interaction between fluconazole (Flu) and amphotericin B (AmB) was evaluated in a murine model of systemic candidiasis for one Flu-susceptible strain (MIC, 0.5 µg/ml), two strains with intermediate Flu resistance (Flu mid-resistant strains) (MIC, 64 and 128 µg/ml), and one highly Flu-resistant strain (MIC, 512 µg/ml) of Candida albicans. Differences in fungal densities in kidneys of infected mice after 24 h of therapy and in survival rates at 62 days of mice treated with an antifungal drug or a combination of antifungal drugs for 4 days were compared. For the Flu-susceptible and Flu mid-resistant strains, the combination of Flu and AmB was antagonistic, as shown by both quantitative culture results and survival. The interaction was additive for the highly Flu-resistant strain. These results suggest that the combination of Flu and AmB should be used with caution in infections due to fungi that are usually susceptible to both antifungal agents and as empirical antifungal drug therapy.


* Corresponding author. Mailing address: Division of Infectious Diseases, Mail Code-49, Albany Medical College, 47 New Scotland Ave., Albany, NY 12208. Phone: (518) 262-6548. Fax: (518) 262-6727. E-mail: arnold_louie_at_amc01-3{at}ccgateway.amc.edu.


Antimicrobial Agents and Chemotherapy, December 1999, p. 2841-2847, Vol. 43, No. 12
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Cacciapuoti, A., Gurnani, M., Halpern, J., Norris, C., Patel, R., Loebenberg, D. (2005). Interaction between Posaconazole and Amphotericin B in Concomitant Treatment against Candida albicans In Vivo. Antimicrob. Agents Chemother. 49: 638-642 [Abstract] [Full Text]  
  • Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., Ghannoum, M. A. (2005). Combination Treatment of Invasive Fungal Infections. Clin. Microbiol. Rev. 18: 163-194 [Abstract] [Full Text]  
  • MacCallum, D. M., Odds, F. C. (2004). Need for Early Antifungal Treatment Confirmed in Experimental Disseminated Candida albicans Infection. Antimicrob. Agents Chemother. 48: 4911-4914 [Abstract] [Full Text]  
  • Cuenca-Estrella, M. (2004). Combinations of antifungal agents in therapy-what value are they?. J Antimicrob Chemother 54: 854-869 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Maracci, M., Fothergill, A. W., Baldassarri, I., Rinaldi, M. G., Scalise, G. (2004). In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata. Antimicrob. Agents Chemother. 48: 3317-3322 [Abstract] [Full Text]  
  • Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
  • Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C., Burnie, J. (2003). Preclinical Assessment of the Efficacy of Mycograb, a Human Recombinant Antibody against Fungal HSP90. Antimicrob. Agents Chemother. 47: 2208-2216 [Abstract] [Full Text]  
  • Andes, D. (2003). In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis. Antimicrob. Agents Chemother. 47: 1179-1186 [Full Text]  
  • Petraitis, V., Petraitiene, R., Groll, A. H., Sein, T., Schaufele, R. L., Lyman, C. A., Francesconi, A., Bacher, J., Piscitelli, S. C., Walsh, T. J. (2001). Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis. Antimicrob. Agents Chemother. 45: 471-479 [Abstract] [Full Text]  
  • Louie, A., Kaw, P., Banerjee, P., Liu, W., Chen, G., Miller, M. H. (2001). Impact of the Order of Initiation of Fluconazole and Amphotericin B in Sequential or Combination Therapy on Killing of Candida albicans In Vitro and in a Rabbit Model of Endocarditis and Pyelonephritis. Antimicrob. Agents Chemother. 45: 485-494 [Abstract] [Full Text]  
  • Louie, A., Liu, W., Miller, D. A., Sucke, A. C., Liu, Q.-F., Drusano, G. L., Mayers, M., Miller, M. H. (1999). Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosine Monotherapies in Treatment of Experimental Endocarditis, Endophthalmitis, and Pyelonephritis Due to Candida albicans. Antimicrob. Agents Chemother. 43: 2831-2840 [Abstract] [Full Text]